期刊文献+

(1S,3aR,6aS)-八氢环戊二烯并[c]吡咯-1-羧酸叔丁酯草酸盐的合成 被引量:1

Synthesis of (1S,3aR,6aS)-t-Butyl Octahydrocyclopenta[c]pyrrole-1-carboxylate Oxalate
原文传递
导出
摘要 2-[N-(N'-苄基-L-脯氨酰)氨基]二苯甲酮的甘氨酸席夫碱Ni(Ⅱ)配合物,可立体选择性地与1-环戊烯甲醛发生Michael加成,并经酸性水解得(3aR,6aS)-1,3a,4,5,6,6a-六氢环戊二烯并[c]吡咯-1-羧酸,再经氢化还原、氨基保护和(S)-1,2,3,4-四氢-1-萘胺的手性拆分得(1S,3aR,6aS)-2-(叔丁氧羰基)八氢环戊二烯并[c]吡咯-1-羧酸,然后通过酯化、脱氨基保护基和成盐反应得特拉匹韦关键中间体(1S,3aR,6aS)-八氢环戊二烯并[c]吡咯-1-羧酸叔丁酯草酸盐,总收率约40%。 (1S,3aR,6aS)-t-Butyl octahydrocyclopenta[c]pyrrole-1-carboxylate oxalate,the key intermediate of telaprevir,was synthesized from (S)-glycine-nickel-(S)-2-[N-(N'-benzyl-L-proplyl) amino] benzophenone via stereospecific Michael addition with cyclopent-l-enecarbaldehyde and acid hydrolysis to give (3aR,6aS)-1,3a,4,5,6,6a-hexahydrocyclopenta[c]pyrrole-1-carboxylic acid,which was subjected to hydrogenation reduction,amino protection,chiral resolution in the presence of (S)-1,2,3,4-tetrahydro-1-naphthylammonium,esterification,amino deprotection and salinization with an overall yield of about 40%.
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2014年第11期1012-1015,共4页 Chinese Journal of Pharmaceuticals
基金 宁波市自然科学基金项目(2013A610089)
关键词 (1S 3aR 6aS)-八氢环戊二烯并[c]吡咯-1-羧酸叔丁酯 特拉匹韦 合成 中间体 (1S,3aR,6aS)-t-butyl octahydrocyclopenta [c] pyrrole-1-carboxylate telaprevir synthesis intermediate
  • 相关文献

参考文献9

  • 1Revill P, Serradell N, Bolos J, et al. Telaprevir [J]. Drugs Future, 2007, 32 (9) : 788-798.
  • 2薛燕,王哲烽,钟静芬.特拉匹韦合成路线图解[J].中国医药工业杂志,2013,44(4):404-407. 被引量:2
  • 3Ding HX, Liu KKC, Sakya SM, et al. Synthetic approaches to the 2011 new drugs [J]. Bioorg Med Chem, 2013, 21 (11) : 2795-2825.
  • 4Tanoury G J, Chen M, Cochran JE. Processes and intermediates: WO, 2007022459 [P]. 2007-02-22.
  • 5Tanoury GJ. Processes and intermediates: WO, 2012158513 [P]. 2012-11-22.
  • 6Hung KY, Harris PW, Brimble MA. Synthesis of methyl N-boc- (2S,4R) -4-methylpipecolate [J]. J Org Chem, 2010, 75 (24) : 8728-8731.
  • 7K6hler V, Bailey KR, Znabet A, et al. Enantioselective biocatalytic oxidative desymmetrization of substituted pyrrolidines [J]. Angew Chem Int Ed Engl, 2010, 49(12) : 2182-2184.
  • 8Tanoury G J, Chen M, Cochran JE, et al. Processes and intermediates: US, 20100063252 [P]. 2010-03-11.
  • 9Wang J, Shi T, Deng G, et al. Highly enantio- and diastereoselective Mannich reactions of chiral Ni ( II ) glycinates with amino sulfones. Efficient asymmetric synthesis of aromatic ct,13-diamino acids [J]. J Org Chem, 2008, 73 (21) : 8563-8570.

二级参考文献17

  • 1Tanoury GJ, Chen M, Cochran J. Processes and intermediates: WO, 2007022459 [P]. 2006-08-18.
  • 2Gerald T, Chen M, Cochran J, et al. Processes and intermediate: US, 20100063252 [P]. 2009-04-27.
  • 3K/Shler V, Bailey KR, Znabet A, et al. Enantioselective biocatalytic oxidative desymmetrization of substituted pyrrolidine [J]. Angew Chem Int Ed Engl, 2010, 49(12): 2182-2184.
  • 4Francois M,Young C J, Jerry T, et al. In vitro and in vivo isotope effects with Hepatitis C protease inhibitors:Enhanced plasma exposure of deuterated telaprevir versus telaprevir inrats EJ]. JMed Chem, 2009, 52: 7993-8001.
  • 5塔努里GJ,陈M,雍YC,等.用于制备立体化合物的方法和中间体:中国,101454274[P].2006-03.16.
  • 6Edward S,Timothy DO, Khanh N, et al. New synthetic technology for efficient construction of et-hydroxy-13-amino amides via the passerine reaction [J]. Organic Lett, 2000, 2 (18) : 2769-2772.
  • 7Srikanth V, Francisco V, Wanli W, et al. Potent ketoamide inhibitors of HCV NS3 protease derived from quatemized P~ groups [J]. Bioorg Med Chem Lett, 2010, 20:2151-2155.
  • 8Michael G, John OL, Chandrasekar V. HCV inhibitors: US, 2007005864 [P]. 2007-03-08.
  • 9Dener J. Process for the preparation of (3S) -3-amino- N-cyclopropyl-2-hydroxyalkamide derivatives: WO, 2009114633 [P]. 2009-09-17.
  • 10Perni RB, Mingzhang C, Jung YC, et al. Deuterated ated hepatitis C protease inhibitors: WO, 2007109080 [P]. 2007-09-27.

共引文献1

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部